Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	32.59B
Revenue (ttm)	12.60B
Net Income (ttm)	2.24B
Shares Out	n/a
EPS (ttm)	2.46
PE Ratio	14.54
Forward PE	13.76
Dividend	1.20 (4.02%)
Ex-Dividend Date	Jun 13, 2025

Volume	1,226,740
Average Volume	1,906,149
Open	30.25
Previous Close	29.95
Day's Range	29.40 - 30.25
52-Week Range	23.10 - 34.00
Beta	0.34
RSI	54.55
Earnings Date	Aug 21, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric-coated tablets and ilaprazole sodium for injection a series of bismuth potassium citrate products for gastrointestinal field; leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for assisted reproduction field; fluvoxamine maleate and perospirone hydrochloride tablets for psychiatric...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY